NICE does not recommend eribulin for people with locally advanced or metastatic breast cancer that has got worse after two or more courses of chemotherapy.

Why has NICE said this?

NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. Eribulin does not provide enough benefit to patients to justify its high cost, so NICE did not recommend it.

Get involved